Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus - 26/07/17
, Julie M. Zito, PhD a, Daniel J. Safer, MD b, Laurence S. Magder, PhD a, Susan dosReis, PhD a, Fadia T. Shaya, PhD, MPH a, Geoffrey L. Rosenthal, MD, PhD aAbstract |
Objective |
More than half of youth treated with atypical antipsychotic (AAP) medications are also treated with concomitant antidepressants or stimulants. This study assessed the association between antidepressant or stimulant use concomitant with AAPs and the risk of incident type 2 diabetes mellitus (T2DM).
Method |
Medicaid Analytic eXtract data were used to conduct a retrospective cohort study of youth (aged 5–20 years) who initiated AAP treatment. In AAP-treated youth, concomitant antidepressant (selective serotonin reuptake inhibitors [SSRI]/serotonin-norepinephrine reuptake inhibitors [SNRIs], tricyclic/other cyclic antidepressants [TCAs], and other antidepressants) or stimulant use was assessed. The risk of incident T2DM was estimated using discrete time failure models, adjusting for disease risk score estimated using >125 baseline and time-dependent covariates.
Results |
Among 73,224 AAP initiators, 43.0% had concomitant antidepressant use (76.4% were SSRI/SNRIs) and 43.8% had concomitant stimulant use. The study cohort had an average follow-up of 24.8 months (median = 22.0 months, interquartile range [IQR] = 10.0–38.0 months). In current AAP-treated youth, concomitant SSRI/SNRI (relative risk [RR] = 1.84, 95% CI = 1.30–2.59) or TCA use (RR = 2.75, 95% CI = 1.28–5.87) was associated with an increased risk of T2DM. By contrast, concomitant use of other antidepressants or stimulants with AAPs was not associated with an increased risk of T2DM. In concomitant users of AAPs and SSRI/SNRIs, the risk of T2DM increased with the duration of SSRI/SNRI use (RR = 2.35, 95% CI = 1.15–4.83 for ≥180 days vs. 1–180 days) as well as with the cumulative SSRI/SNRI dose (RR = 1.99, 95% CI = 1.08–3.67 for >2,700 mg vs. 1-2,700 mg fluoxetine dose equivalents), after adjusting for the duration and cumulative dose of AAP use. By contrast, in concomitant users of AAPs and stimulants, neither duration nor cumulative dose of stimulants was associated with an increased risk of T2DM.
Conclusion |
In AAP-treated Medicaid-insured youth, concomitant SSRI/SNRI use was associated with a heightened risk of T2DM, which intensified with increasing duration and dose.
Le texte complet de cet article est disponible en PDF.Key words : type 2 diabetes mellitus, atypical antipsychotics, antidepressants, stimulants, Medicaid
Plan
| An interview with the author is available by podcast at www.jaacap.org |
|
| Article can be used to obtain continuing medical education (CME) at www.jaacap.org. |
|
| This article is discussed in an editorial by Drs. Christoph U. Correll and Britta Galling on page 634. |
|
| The study was supported, in part, by the University of Maryland, Baltimore and, in part, by a grant from the US Food and Drug Administration (1U01FD004320). The supporting organizations had no role in the design, conduct, or reporting of the study. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views and opinions of the supporting organizations. |
|
| The preliminary findings from this study were presented at the 2016 Mid-Year Meeting of the International Society for Pharmacoepidemiology, Baltimore, MD, April 10–12, 2016. This study is also a part of Dr. Burcu’s doctoral dissertation. |
|
| Drs. Burcu and Magder served as the statistical experts for this research. |
|
| Disclosure: Drs. Burcu, Zito, Safer, Magder, dosReis, Shaya, and Rosenthal report no biomedical financial interests or potential conflicts of interest. |
Vol 56 - N° 8
P. 642-651 - août 2017 Retour au numéro
Article précédent
- Network Psychiatry: Computational Methods to Understand the Complexity of Psychiatric Disorders
- Glenn N. Saxe
- Depression and Violence in Adolescence and Young Adults: Findings From Three Longitudinal Cohorts
- Rongqin Yu, Mikko Aaltonen, Susan Branje, Tiina Ristikari, Wim Meeus, Katariina Salmela-Aro, Guy M. Goodwin, Seena Fazel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?